Astria Therapeutics, Inc.

Astria Therapeutics, Inc. is a US-based biopharmaceutical company dedicated to developing innovative therapies for hereditary angioedema and atopic dermatitis, focusing on improving patient outcomes through advanced treatments. Astria Therapeutics was founded in 2008 and is headquartered in Boston, US. The company is focused on creating therapeutics for chronic inflammatory conditions.

In October 2025, BioCryst Pharmaceuticals, Inc. agreed to acquire Astria Therapeutics for USD 700 million, which marks a significant pivot in the company’s business strategy. Astria Therapeutics specializes in the development of innovative therapies aimed at addressing hereditary angioedema (HAE) and atopic dermatitis. Their flagship product, Navenibart (STAR-0215), is designed to provide life-changing treatments for patients suffering from these conditions.

Navenibart functions by inhibiting specific pathways involved in the inflammatory response, thereby reducing the frequency and severity of HAE attacks. Developed through extensive clinical trials, this therapeutic candidate is targeted toward both patients and healthcare providers, particularly in markets such as North America and Europe. Astria's commitment to understanding patient needs shapes its product offerings, ensuring that they are tailored to the experiences and requirements of the end users they serve, which include individuals affected by HAE and atopic dermatitis, as well as the broader healthcare community. The revenue model for Astria Therapeutics is primarily structured around the commercialization of its therapeutic products through partnerships and direct-to-consumer channels.

Transactions typically occur through agreements with healthcare institutions and specialty pharmacies, where products like Navenibart are prescribed directly to patients or offered in clinical settings. The company may also engage in collaborations with research institutions for further development and distribution, facilitating access to their therapies. While specific pricing plans for the therapies are not disclosed, they reflect prevailing market rates for specialty pharmaceuticals, aligning with industry standards for innovative treatments targeting chronic conditions. Astria's focus on providing effective solutions for patients supports their mission of improving patient outcomes in the therapeutic areas they serve.

In October 2025, BioCryst Pharmaceuticals, Inc. will acquire Astria Therapeutics, enhancing its services and business development. With the upcoming acquisition, Astria is expected to focus on the development and commercialization of new therapeutic products. Specific plans for expanding into new markets have not been detailed, but continued growth in existing therapeutic areas is anticipated.